Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics posts Q2 net loss of $4.8 million as revenue falls to $0.6 million

Negative Impact 4 of 5 earnings Written later

Atara reported a second-quarter 2026 net loss of $4.8 million, or $(0.32) per share, compared with net income of $2.4 million, or $0.20 per basic share, a year earlier. Revenue fell to $0.6 million from $17.6 million, mainly because deferred revenue was recognized in 2025 after development moved to Pierre Fabre. The company says it expects to fund operations into mid-2027, but cash stood at $9.9 million at June 30, 2026.

Key points

  • Commercialization revenue was $0.6 million for Q2 2026, down from $17.6 million in Q2 2025.
  • Net loss was $4.8 million, or $(0.32) per share, versus net income of $2.4 million in Q2 2025.
  • Cash, cash equivalents and short-term investments totaled $9.9 million at June 30, 2026, and are expected to fund planned operations into mid-2027.
  • Total costs and operating expenses fell to $5.4 million from $14.4 million a year earlier; a Type A meeting with the FDA on tabelecleucel was described as productive, with a regulatory update expected later in the quarter.

The filing

CompanyAtara Biotherapeutics, Inc. (ATRA)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:10 PM ET
Accession number0001193125-26-346857

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.